Abstract
Chemotherapy-related nausea and vomiting can today be controlled with available antiemetics in a high percentage of patients but emesis remains a problem for some patients, with certain drugs and with repeated cycles of chemotherapy. The fundamental steps of clinical research in antiemetics towards the improvement of the control of nausea and vomiting with new drugs or combinations are presented. Special emphasis is given to cisplatin-induced nausea and vomiting because of the frequency and relevance of this phenomenon. The use of high-dose metoclopramide, its combination with steroids, and later the addition of lorazepam or diphenhydramine represented the evolving standard of the 1980s, with the level of complete protection from vomiting improving from 30%–40% to 60%–70% with the three-drug combination. The introduction of new agents such as the 5-hydroxytryptamine 3 (5-HT3) receptor antagonists has recently offered new possibilities because of their activity and lack of toxicity. In particular, the combination of ondansetron plus dexamethasone is today the most efficacious and least toxic antiemetic treatment for prevention of emesis in patients treated with a single high dose or low repeated doses of cisplatin. A comparison of different 5-HT3 antagonists, always in combination with steroids, is now considered necessary. For patients treated with moderately emetogenic chemotherapy the use of steroids can still be considered the standard treatment. In this setting, the role of 5-HT3 receptor antagonists, alone or in combination with steroids, has to be better defined through large, well-planned clinical trials, which should have a cost-effectiveness analysis as one of their goals.
Similar content being viewed by others
References
Allan SG, Cornbleet MA, Warrington PS, et al (1984) Dexamethasone and high-dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J 13:235–237
Andrews PLR, Rapeport WG, Sanger GJ (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 9:334–341
Ballard HS, Bottino G, Bottino J (1992) Ondansetron and chest pain (letter). Lancet 340:1107
Basurto C, Roila F, Bracarda S, et al (1988) A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in coimbination with other antiblastic agents. Am J Clin Oncol 11:594–596
Basurto C, Roila F, Del Favero A, et al (1988) A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Cancer Invest 6:475–479
Beck TM, Madajewicz S, Navari RM, et al (1992) A double-blind, stratified, randomized comparison of intravenous (iv) ondansetron administered as a multiple dose regimen versus two single dose regimens in the prevention of cisplatin-induced nausea and vomiting. Proc Am Soc Clin Oncol 11:378
Bécouarn Y, Bui NB, David M, et al (1986) Improved control of cis-platin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial. Eur J Cancer Oncol 22:1421–1424
Benrubi GI, Norvell M, Nuss RC, et al (1985) The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cisplatin. Gynecol Oncol 21:306–313
Blackwell CP, Harding SM (1989) The clinical pharmacology of ondasetron. Eur J Cancer Clin Oncol 25:521–524
Bonneterre J, Chevallier B, Metz R, et al (1990) A randomized doubleblind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8:1063–1069
Burton G, Huang A, Lazarus H, et al (1990) A double-blind randomized comparison of three doses of i.v. ondansetron for prevention of emesis induced by multi-day cisplatin therapy. Proc Am Soc Clin Oncol 9:328
Castle WM, Cunningham K, Kanarek BB (1992) Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure (letter). Ann Oncol 3:773–774
Chevallier B, on behalf of the Granisetron Study Group (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26 [Suppl 1]:33–36
Chiara S, Scarfi P, Campora E, et al (1984) Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy-induced nausea and vomiting. Chemioterapia 3:333–336
Chiara S, Campora E, Lionetto R, et al (1987) Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10:264–267
Coates A, Abraham S, Kaye SB, et al (1983) On the receiving end—patient perception of the side-effects of cancer chemo-therapy. Eur J Cancer Clin Oncol 19:203–208
Coates AS, Childs A, Cox K, et al (1992) Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. Ann Oncol 3:719–722
Cognetti F, Pinnarò P, Carlini P, et al (1984) Randomized open crossover trial between metoclopramide (MCP) and dexamethasone (DXM) for the prevention of cisplatin induced nausea and vomiting. Eur J Cancer Clin Oncol 20:183–187
Cunningham D, Turner A, Hawthorn J, et al (1989) Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet I:1323
Dana BW, Everts EC, Dickinson D (1985) Dexamethasone vs placebo for cisplatin induced emesis. A randomized cross-over trial. Am J Clin Oncol 8:426–428
David M, Durand M, Chauvergne J, et al (1984) Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide. Cancer Treat Rep 68:921–922
De Haan LD, De Mulder PHM, Beex LVAM, et al (1988) The efficacy of GR38032F an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur J Cancer Clin Oncol 24:1383–1384
De Mulder PHM, Seynaeve C, Vermorken JAB, et al (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:8334–8340
Dicato M (1991) Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 27 [Suppl 1]:518–519
Diehl V, on behalf of the Granisetron Study Group (1992) Fractionated chemotherapy—granisetron or conventional antiemetics? Eur J Cancer 28A [Suppl 1]:21–28
Dobrow RB, Coppock MA, Hosenpud JR (1991) Extrapyramidal reaction caused by ondansetron. J Clin Oncol 9:1921
D'Olimpo JT, Camacho F, Chandra P, et al (1985) Antiemetic efficacy of high-dose dexamethasone vs placebo in patients receiving cisplatin-based chemotherapy: a randomized double blind controlled clinical trial. J Clin Oncol 3:1133–1135
Edge SB, et al (1987) High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. Am J Clin Oncol 10:257–263
Einhorn LH, Nagy C, Werner K, et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731–735
Fetting JH, Grochow LB, Folstein MF, et al (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487–1493
Fetting JH, McCarthy LE, Borison HL, et al (1982) Vomiting induced by cyclophosphamide and phosphoramide mustard in cats. Cancer Treat Rep 66:1625–1629
Fraschini G, Ciociola A, Esparaza L, et al (1991) Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 9:1268–1274
Frustaci S, Grattoni E, Tumolo S, et al (1986) Randomized cross-over antiemetic study in cisplatin treated patients. Comparison between high-dose IV metoclopramide and high-dose IV dexamethasone. Cancer Chemother Pharmacol 17:75–79
Gralla RJ (1992) Serotonin antagonist antiemetics: progress and concerns (editorial). Ann Oncol 3:677–678
Gralla RJ, Braun TJ, Squillante A, et al (1981) Metoclopramide: initial clinical studies of high dosage regimen in cisplatin-induced emesis. In: Poster D (ed) The treatment of nausea and vomiting induced by cancer chemotherapy. Masson, New York, pp 167–176
Gralla RJ, Itri LM, Piski SE, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909
Grunberg SM, Stevenson LL, Russell CA, et al (1989) GR38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705
Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721–728
Hainsworth JD, Omura GA, Khoiasteh A, et al (1991) Ondansetron (GR38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy. Am J Clin Oncol 14:336–340
Hawthorne J, Cunningham D (1990) Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 61:56–60
Hesketh PJ, Murphy WK, Lester EP, et al (1989) GR38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705
Hesketh PJ, Twaddell T, Finn A (1990) A possible role for cisplatin in the transient hepatic enzyme elevations noted after ondansetron administration. Proc Am Soc Clin Oncol 9:323
Higgins GA, Kilpatrick GJ, Bruce KT, et al (1989) 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247–255
Homesley HD, Gainey JM, Jobson VN, et al (1982) Double-blind placebo-controlled study of metoclopramide in cisplatin-induced emesis. N Engl J Med 307:250–251
Italian Group for Antiemetic Research (1992) Ondansetron+dexamethasone vs metoclopramide+dexamethasone+diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340:96–99
Jones AL, Hill AS, Soukop M, et al (1991) Comparison of ondansetron vs dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483–487
Jordan NS, Schauer PK, Schauer A, et al (1985) The effect of administration rate of cisplatin induced emesis. J Clin Oncol 3:559–561
Joss RA, Galeazzi RL, Bischoff AK, et al (1986) The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther 39:619–624
Kaasa S, Kvalov S, Dicato MA, et al (1990) A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, doubleblind study. Eur J Cancer 26:311–314
Kris MG, Tyson LB, Gralla RJ, et al (1983) Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309:433
Kris MG, Gralla RJ, Tyson LB, et al (1985) Improved control of cisplatin induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55:527–534
Kris MG, Gralla RJ, Clark RA, et al (1987) Antiemetic control and prevention of side efects of anticancer therapy with lorezapam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60:2816–2822
Kris MG, Gralla RJ, Clark RA, et al (1988) Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6:659–662
Kris MG, Gralla RJ, Clark RA, et al (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42–46
Lane M, Grunberg SM, Lester EP, et al (1990) A double-blind comparison of three dose levels of i.v. ondansetron in the prevention of cisplatin-induced nausea and vomiting. Proc Soc Clin Oncol 9:329
Markman M, Sheidler V, Ettinger DS, et al (1984) Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311:549–552
Marschner NW, Adler M, Nagel GA, et al (1991) Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27:1137–1140
Marty M, Droz JP, Pouillart P, et al (1989) GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 23:389–391
Marty M, on behalf of the Granisetron Study Group (1990) A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chloropromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26 [Suppl 1]: 28–32
Marty M, d'Allens H, et le Groupe Multicentrique Francais (1990) Etude randomisée en double-insu comparant l'efficacité de l'ondansetron selon deux modes d'administration: injection unique et perfusion continue. Cah Cancer 2:541–546
Marty M, Pouillart P, School S, et al (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821
Mellink WA, Blinihim GH, Van Deyk WA (1984) Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. Eur J Cancer Clin Oncol 20:1147–1150
Metz CA, Freedman RS, Magrina JF (1987) Methylprednisolone in cisplatin induced nausea and emesis: a placebo-controlled trial. Gynecol Oncol 27:84–89
Morran C, Smith DC, Anderson DA, et al (1979) Incidence of nausea and vomiting with cytotoxic chemotherapy. A prospective randomized trial of antiemetics. Br Med J 1:1323–1324
Peroutka SJ, Snyder SH (1982) Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet I:658–659
Pollera CF, Nardi M, Marolla P, et al (1989) Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol 12:524–529
Roila F, Tonato M, Basurto C, et al (1985) Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep 69:1353–1357
Roila F, Tonato M, Basurto C, et al (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141–149
Roila F, Tonato M, Basurto C, et al (1987) Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with iv CMF. Eur J Cancer Clin Oncol 23:615–617
Roila F, Basurto C, Minotti V, et al (1988) Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide, methotrexate, 5-fluorouracil: a double-blind randomized study. Oncology 45:346–349
Roila F, Tonato M, Basurto C, et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693–1700
Roila F, Bracarda S, Tonato M, et al (1990) Ondansetron (GR38032F) in the prophylaxis of acute and delayed cisplatin0induced emesis. Clin Oncol 2:268–272
Roila F, Basurto C, Bracarda S, et al (1991) Double-blind crossover trial of single vs divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. Eur J Cancer 27:119–121
Roila F, Tonato M, Cognetti F, et al (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675–678
Roila F, Tonato M, Del Favero A (1991) Publication of unethical studies on the treatment of chemotherapy-induced emesis. J Clin Oncol 9:891
Saller R, Hellenbrecht D (1985) Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against antiemetic-induced emesis. Cancer Treat Rep 69:1301–1303
Schallier D, Van Belle S, De Greve J, et al (1985) Methylprednisolone as an antiemetic drug. A randomized double blind study. Cancer Chemother Pharmacol 14:235–237
Seynaeve C, Schuller J, Buser K, et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomized, parallel group study. Br J Cancer 66:192–197
Shinkai T, Saii N, Eguchi K, et al (1986) Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol 16:279–287
Sledge GW, Einhorn LH, Nagy C, et al (1990) Randomized trial of ondansetron and metoclopramide as antiemetic therapy for cisplatin-based chemotherapy. Proc Am Soc Clin Oncol 9:323
Smaldone L, Al-Sarraf M, Aapro M, et al (1991) Randomized double-blind crossover comparison of batanopride (BMY-25801) and metoclopramide (MTC) in patients receiving cisplatinbased chemotherapy. Proc Am Soc Clin Oncol 10:342
Smaldone L, Murphy R, Gralla R, et al (1991) Antiemetic activity of batanopride (BMY-25801) in patients receiving cisplatin: a randomized double-blind parallel comparison of two doses. Proc Am Soc Clin Oncol 10:326
Smith DB, Newlands ES, Spruyt OW, et al (1990) Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 61:323–324
Smith DB, Newlands ES, Rustin GJS, et al (1991) Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338:487–490
Smith IE, on behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 26 [Suppl 1]:19–23
Smith RH (1989) Safety of ondansetron. Eur J Cancer Clin Oncol 25:547–550
Smyth JF, Coleman RE, Nicolson M, et al (1991) Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 303:1423–1426
Sorbe B, Frankendal B, Glimelius B, et al (1990) A multicentre randomized study comparing the anti-emetic effects of the 5-HT3 antagonist IC5 205-930 with a metoclopramide-containing anti-emetic cocktail in patients receiving cisplatin chemotherapy. Ann Oncol 1 [Suppl]:113
Soukop M, on behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26 [Suppl 1]:15–19
Strum SB, McDermed JE, Liponi DF (1985) High-dose intravenous metoclopramide vs combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind cross-over comparison of antiemetic efficacy. J Clin Oncol 3:245–251
Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107–114
Tyers MD, Bunce KT, Humphrey PPA (1989) Pharmacological and antiemetic properties of ondansetron. Eur J Cancer Clin Oncol 25 [Suppl 1]:15–19
Venner P, for the clinical trials group of National Cancer Institute of Canada (1990) Granisetron for high dose cisplatin induced emesis: a randomized double blind study. Proc Am Soc Clin Oncol 9:320
Warr D, Willan A, Fine S, et al (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83:1169–1173
Weissbach L, for the Multi-day Cisplatin Emesis Study Group (1991) Ondansetron. Lancet 338:753
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tonato, M., Roila, F., Del Favero, A. et al. Antiemetics in cancer chemotherapy: historical perspective and current state of the art. Support Care Cancer 2, 150–160 (1994). https://doi.org/10.1007/BF00417473
Issue Date:
DOI: https://doi.org/10.1007/BF00417473